secwatch.observer — SEC 8-K summary
======================================

Issuer:     Anika Therapeutics, Inc. (ANIK)
CIK:        0000898437
Form:       8-K
Filed at:   2026-07-14T21:00:16+00:00
Accession:  0001171843-26-004635
Event type: debt
Sentiment:  neutral
Materiality: 0.45
Item codes: 1.01, 2.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Anika Therapeutics enters Fifth Amendment to credit agreement, $50M revolver due 2031
--------------------------------------------------------------------------------

- $50M senior revolving credit facility with Bank of America, maturity July 10, 2031.
- Option to increase commitments by up to $50M (total $100M) subject to lender approval.
- Interest rate: SOFR plus 0.25%-1.25% based on leverage ratio; commitment fee 0.20%-0.30% on unused portion.
- Financial covenants include max leverage and interest coverage ratios; first-priority lien on substantially all assets.
- Amendment reduces revolving facility from prior amount to $50M; certain lenders exit.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/0001171843-26-004635-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/898437/000117184326004635/f8k_071426.htm
  HTML page:      https://secwatch.observer/filing/0001171843-26-004635

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer